<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List
href="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/filelist.xml">
<link rel=Edit-Time-Data
href="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>DD on ATNF</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Alco van Zoeren</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Alco van Zoeren</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>6</o:TotalTime>
  <o:Created>2021-01-27T12:35:00Z</o:Created>
  <o:LastSaved>2021-01-27T12:35:00Z</o:LastSaved>
  <o:Pages>8</o:Pages>
  <o:Words>2669</o:Words>
  <o:Characters>14680</o:Characters>
  <o:Lines>122</o:Lines>
  <o:Paragraphs>34</o:Paragraphs>
  <o:CharactersWithSpaces>17315</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData
href="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/themedata.thmx">
<link rel=colorSchemeMapping
href="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:HyphenationZone>21</w:HyphenationZone>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>NL</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hashtag"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Unresolved Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073732485 9 0 511 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
	{mso-style-priority:99;
	color:#0563C1;
	mso-themecolor:hyperlink;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:#954F72;
	mso-themecolor:followedhyperlink;
	text-decoration:underline;
	text-underline:single;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:70.85pt 70.85pt 70.85pt 70.85pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:Standaardtabel;
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin-top:0cm;
	mso-para-margin-right:0cm;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=NL link="#0563C1" vlink="#954F72" style='tab-interval:35.4pt;
word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>DD on ATNF
180 Life Sciences Corp.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>TLDR;<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Amazing
team (top of the world). This team discovered this class of drugs and are
basically applying it to unmet condition. The founder, Godfather of cannabinoid
chemistry: Prof Raphael <span class=SpellE>Mechoulam</span>, discovered the
body’s endocannabinoid system. Scientific team and founders are pioneers with
proven track record in drug discovery from the University of Oxford, Hebrew
University and Stanford University. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Developing
three families of novel drugs addressing significant market opportunities in
inflammation, fibrosis and pain: <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>• Fibrosis
&amp; Anti-TNF <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>• Synthetic
CBD <span class=SpellE>Analogs</span> (SCAs) <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>• a7nAChR <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Multiple
programs in synchronized stages of development combined with IP portfolio
reduces risk.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Numerous
near-term inflection points for anti-TNF programs: one program late stage 2b/3
trial, two additional clinical programs projected to start Q3/4 2021 with NIHR
grant awarded. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>• Initial
clinical anti-TNF clinical trials funded by investments and grants (UK). <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>•
Regulatory approvals obtained from the UK Medicines and Healthcare Products Regulatory
Agency (MHRA) and the Dutch Centrale <span class=SpellE>Commissie</span> <span
class=SpellE>Mensgebonden</span> <span class=SpellE>Onderzoek</span> (CCMO) and
the relevant accredited ethics committees to perform clinical trials in the UK
and The Netherlands for anti-TNF products.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Three
anti-inflammatory therapeutic programs potentially used in combination.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Pipeline is
good for a 150B market. Phase 3 results for a 4.5B treatment Q4 2021.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Ticker:
ATNF, NASDAQ, current price: $3.74<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Description<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>180 Life
Sciences is developing new treatments for one of the world's biggest drivers of
disease: inflammation.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The company
consists of three programs developing novel drugs for treating distinct
inflammatory diseases. These programs are led by world-leading scientists at
prestigious universities who have already developed blockbuster drugs and made
ground-breaking discoveries in their fields. One of the programs is conducting
a phase 2b/3 trial and expects its first results in Q4 2021. Other clinical
trials are expected to begin by the end of 2021. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'><a
href="https://180lifesciences.com/about/">https://180lifesciences.com/about/</a>
<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>To say this
will eventually be a multi $BILLION company seems like an understatement.
($4.5B market size for Drug with late stage result later in the year- with Huge
$ pipeline in early phases. Almost all are grant funded thanks to the teams
reputation). ATNF stands for Anti-TNF, the world’s largest class of drugs
(expected to grow to $150B by 2025).<span style='mso-spacerun:yes'>  </span>$ATNF
Team member Prof Sir Marc Feldman (Oxford) pioneered Anti-TNF therapy.<span
style='mso-spacerun:yes'>  </span>Feldman, along with $ANTF president <span
class=SpellE>Dr.</span> James Woody used this to discover Remicade (which
J&amp;J acquired for over $5 Billion). TNF inhibitor drugs use monoclonal
antibodies to treat autoimmune and inflammatory conditions: psoriasis, IBD,
asthma, Crohn’s disease, cancers, rheumatoid arthritis, etc.... <span
class=SpellE>ie</span>, Enbrel, Humira, Remicade. Additionally, Cannabinol has
been discovered to have natural Anti-TNF properties. $ATNF team member Prof
Raphael <span class=SpellE>Mechoulam</span> is a Cannabinoid Pioneer, who
Discovered the body’s endocannabinoid system.<o:p></o:p></span></p>

<p class=MsoNormal><a
href="https://www.biospace.com/article/180-life-sciences-poised-to-break-ground-with-anti-tnf-program/"><span
lang=EN-GB style='mso-ansi-language:EN-GB'>https://www.biospace.com/article/180-life-sciences-poised-to-break-ground-with-anti-tnf-program/</span></a></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The company
had a strong IP portfolio with a long lifespan, providing coverage up to 2039. <b><br
clear=all style='mso-special-character:line-break;page-break-before:always'>
<o:p></o:p></b></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Pipeline
&amp; Development Programs<o:p></o:p></span></b></p>

<p class=MsoNormal><span style='mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Afbeelding_x0020_7" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:381.6pt;height:219.6pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image001.png"
  o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=509 height=293
src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image002.jpg"
v:shapes="Afbeelding_x0020_7"><![endif]></span><span lang=EN-GB
style='mso-ansi-language:EN-GB'><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Currently
the company has 3 programs running, 1 of the running programs is in clinical
stage. The program in clinical stage is the Fibrosis &amp; anti-TNF program. By
repurposing of anti-TNF for major unmet needs the company targets early stage <span
class=SpellE>Dupuytren’s</span> disease (currently stage 2b/3 with results in
Q4 2021), Frozen Shoulder and POCD on the near term and NASH further out. There
is no treatment for early stage <span class=SpellE>Dupuytren’s</span> disease (3B
market in the USA and 1,5B market in the EU).<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Phase 2
results exceeded expectations and are very promising for the phase 3 results end
of this year.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Woody said
spaces like RA are “pretty well covered,” but noted there are other areas where
this type of medication could benefit millions of people, such as early <span
class=SpellE>Dupuytren's</span> contracture, a fibrotic disease of the hand.
There are approximately 11 million people in the United States, including
Woody’s wife, and a similar number in Europe who are afflicted with this
painful condition that can cause the hand to curl up into a claw.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>180 Life
Sciences is currently assessing its TNF inhibitor in a Phase II/III program.
Results from this study are expected in the second half of this year. Obtaining
results from the ongoing study have been delayed due to the COVID-19 pandemic,
Woody said.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Another
space 180 is assessing its anti-TNF program is in frozen shoulder, a condition
characterized by stiffness and pain in the shoulder joint. Woody said this is
an extremely painful condition due to fibrosis in the shoulder joint. They
believe the fibrosis process is similar to what has been seen in early <span
class=SpellE>Dupuytren's</span> contracture and will assess the company’s
anti-TNF asset during a study expected to begin in the third quarter of this
year.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The third
area for 180’s anti-TNF program is in post-operative cognitive delirium
disorder and dysfunction. This issue arises in older patients who have been
under anaesthesia for an extended period of time due to some surgical
procedures. After the surgery or during the surgery, TNF can be released, which
is a cause of dementia, Woody said. The company believes its program can be
useful to prevent this condition and will conduct a study using their novel
concepts.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>In addition
to those three areas, Woody said the company is also looking at non-alcoholic
steatohepatitis (NASH) as a potential area for its anti-TNF therapy. NASH has
been a difficult area for drug developers to crack, but Woody believes his team
has found a new approach. Using human tissue from surgeries, 180 Life Sciences’
research team has been examining the pathways of damage in the liver and they
believe a release of TNF plays a role in that damage.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>“We think
we can block that. We definitely need some therapies for NASH, that’s for
sure,” Woody said.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>180 Life
Sciences also has some interesting programs in preclinical development. The
company has a program using pharmaceutical-grade oral synthetic cannabidiol <span
class=SpellE>analogs</span> to treat pain that is specifically focused on
arthritis. Woody expects this asset to enter the clinic next year. 180 Life
Sciences also has an &#945;7 Nicotinic Acetylcholine receptor agonist program,
which aims to develop &#945;7nAChR agonists for the treatment of inflammatory
diseases, initially ulcerative colitis induced after cessation of smoking.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Smoking
cessation induced ulcerative colitis may sound like a small addressable
market... but it actually is estimated to account for up to 30% of all UC
cases. Also competitive advantage over biologics b/c it is taken orally (vs
biologic shot) and no side effect profile.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Additional
competitive advantage for all anti-<span class=SpellE>tnf</span> candidates:
This team discovered this class of drugs and are basically applying it to unmet
condition, so high likelihood of success &amp; shorter trial periods expected.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Also some
of the preclinical or very early clinical candidates have insanely big
addressable market for down the road- <span class=SpellE>esp</span> NASH. In
addition to platform of synthetic CBD derivatives anti-TNF for Arthritis...which
would also have competitive advantage over current biologics (which again is a
class development by this team and sold for billions to big pharma) due to not
being shots and much lower risk/ side effects.<o:p></o:p></span></p>

<p class=MsoNormal><span style='mso-no-proof:yes'><!--[if gte vml 1]><v:shape
 id="Afbeelding_x0020_1" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:397.8pt;
 height:183pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image003.png"
  o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=530 height=244
src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image004.jpg"
v:shapes="Afbeelding_x0020_1"><![endif]></span><span lang=EN-GB
style='mso-ansi-language:EN-GB'><o:p></o:p></span></p>

<b><span lang=EN-GB style='font-size:11.0pt;line-height:107%;font-family:"Calibri",sans-serif;
mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:
minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:
EN-US;mso-bidi-language:AR-SA'><br clear=all style='mso-special-character:line-break;
page-break-before:always'>
</span></b>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Team<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>It has the
most impressive management teams of any small cap biotech- regarding experience
and drug to market track records. I challenge anyone to point out a better one.
Here is the latest presentation (management team track records &amp;
experience- along with pipeline info are on slides 3 &amp; 4): <a
href="https://d1io3yog0oux5.cloudfront.net/_c564a2b880eea1d3d5086437298c227f/180lifesciences/db/858/7393/pdf/180LS+Corporate+Presentation+-+12.04.2020+v33.pdf">https://d1io3yog0oux5.cloudfront.net/_c564a2b880eea1d3d5086437298c227f/180lifesciences/db/858/7393/pdf/180LS+Corporate+Presentation+-+12.04.2020+v33.pdf</a>
<o:p></o:p></span></p>

<p class=MsoNormal><span style='mso-no-proof:yes'><!--[if gte vml 1]><v:shape
 id="Afbeelding_x0020_2" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
 height:256.8pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image005.png"
  o:title=""/>
</v:shape><![endif]--><![if !vml]><img border=0 width=605 height=342
src="DD%20on%20ATNF%20180%20Life%20Sciences%20Corp_bestanden/image006.jpg"
v:shapes="Afbeelding_x0020_2"><![endif]></span><b><span lang=EN-GB
style='mso-ansi-language:EN-GB'><o:p></o:p></span></b></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Godfather
of cannabinoid chemistry: Prof Raphael <span class=SpellE>Mechoulam</span></span></b><span
lang=EN-GB style='mso-ansi-language:EN-GB'>. Discovered the body’s
endocannabinoid system.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Professor
Raphael <span class=SpellE>Mechoulam</span>, also known as the “father of
cannabis research,” revealed his latest discovery, <span class=SpellE>cannabidiolic</span>
acid methyl ester (EPM301), only a year ago. The introduction of this new,
patented compound (synthetic, fully stable acid-based cannabinoid molecules)
caused a wave of excitement around the future of medicinal cannabis.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The
compound in question was presented to the world in partnership with EPM, a
global biotechnology company based in the U.S. that aims to bridge the gap
between the cannabis and pharmaceutical industries.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>“EPM
developed a method to work with the original substances of cannabis,” the
Professor explained. “So, while everybody is discussing THC and CBD, these
cannabinoids are actually a secondary substance; they only appear later in the
plant.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>“Originally
there is an acid that appears in the plant, and those acids are these
mysterious worlds of compounds that are much more potent than cannabinoids,” he
added.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>“We compare
our compound not only to cannabinoids, but to the existing drugs that are
applied today,” <span class=SpellE>Mechoulam</span> explained. “So, for
example, in IBD we compared our compounds to two conventional products: one is
the prednisone (the steroids) and one is a biological drug. And in both of
them, we managed to prove that the activity of our compound is very similar to
the common one.”<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>As can be
read in the article below, the patents for EPM301 are not for this company. But
it says a lot about <span class=SpellE>Mechoulam</span> and his reputation. The
SCAs in development at ATNF are comparable to EPM. It’s an alternative to
steroids and opioids. This is a huge market and phase 1 for treatment will
start this Q3 2021.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'><a
href="https://www.forbes.com/sites/javierhasse/2020/07/12/dr-mechoulam/?sh=29d864bb6a45">https://www.forbes.com/sites/javierhasse/2020/07/12/dr-mechoulam/?sh=29d864bb6a45</a><o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Over the
years, the Harvey Prize has become a reliable predictor of the famous Noble
Prize. Since 1986, more than 30% of Harvey laureates were ultimately awarded
the Nobel Prize. In-fact three of them – Professor Jennifer <span class=SpellE>Doudna</span>,
Professor Emmanuelle Charpentier and Professor Reinhard Genzel – are to receive
this year’s Noble Prize!<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Based on
his huge contribution to medical cannabis studies and we can only cross our
fingers and hope that it will be the “Godfather” of cannabis research that will
get next year’s Noble, or the one following it.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'><a
href="https://cbdtesters.co/2020/12/04/prestigious-harvey-prize-goes-to-raphael-mechoulam-the-godfather-of-cannabis-research/">https://cbdtesters.co/2020/12/04/prestigious-harvey-prize-goes-to-raphael-mechoulam-the-godfather-of-cannabis-research/</a>
<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Dr James
Woody</span></b><span lang=EN-GB style='mso-ansi-language:EN-GB'>: Discovered
Remicade (J&amp;J acquired for $5 Billion. Sales of $50 Billion+ since
approval). Founded <span class=SpellE>Avidia</span> and <span class=SpellE>Proteolix</span>
(sold to Amgen). CEO &amp; Founder of <span class=SpellE>Oncomed</span>
Pharma.<span style='mso-spacerun:yes'>  </span>President of Roche Bioscience. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Woody, who
now serves as chief executive officer of 180 Life Sciences, began his career in
drug development as the chief scientific officer and head of research and
development at <span class=SpellE>Centocor</span> Biotech, now a part of the
Johnson &amp; Johnson family.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>During his
time at <span class=SpellE>Centocor</span>, Woody led the team responsible for
developing Remicade, the first of the TNF inhibitor biologics, which has gone
on to become a blockbuster drug with sales of $5 billion in 2019.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>TNF
inhibitors, such as Remicade, are used to stop inflammation. They are popular
treatments in disease like rheumatoid arthritis, psoriatic arthritis, plaque
psoriasis, ankylosing spondylitis, ulcerative colitis (UC) and Crohn's disease.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>Woody was
also the founding CEO of <span class=SpellE>OncoMed</span> Pharmaceuticals,
Inc. and served as president at Roche Bioscience, where he was responsible for
all bioscience research and development, ranging from genetics and genomics to
clinical development of numerous new pharmaceuticals.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>CEO’s
(Woody) wife has <span class=SpellE>Dupuytren’s</span> ... the 1st drug likely
to be approved ($4.5 Billion total addressable market). Not sure what that
means for yearly sales, but no competition or currently approved drugs. Results
in 3rd or 4th quarter of this year.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Prof Sir
Marc Feldman</span></b><span lang=EN-GB style='mso-ansi-language:EN-GB'>:
Oxford. Pioneer of anti-TNF therapy (world’s biggest drug class, $150 Billion+
by 2025). Lead clinical trial for drug Remicade (J&amp;J acquired for $5
Billion).<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>One of the
co-developers of Remicade, Sir Marc Feldmann, a pioneer in anti-TNG therapies,
is also part of Woody’s team at 180 Life Sciences. Feldmann’s research helped
lead to not only the development of Remicade, but it was also licensed by
AbbVie to develop Humira, Woody said. Feldmann is intimately involved in the
development of two of the three projects being developed by 180 Life Sciences,
and is also exploring new uses of anti-TNF and synthetic cannabidiol analogues.
Feldmann serves as co-chairman of the company’s board of directors.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Prof
Lawrence Steinman</span></b><span lang=EN-GB style='mso-ansi-language:EN-GB'>:
Stanford. Founder of <span class=SpellE>Neurocrine</span> Bio. Discovered role
of integrins, Tysabri (Biogen acquired for $3 Billion). Lawrence Steinman, a
professor of Neurology and <span class=SpellE>Pediatrics</span> at Stanford
University, whose research led to the development of multiple sclerosis drug
Tysabri, serves as co-chairman of the company’s board of directors.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Dr
Jonathan Rothbard</span></b><span lang=EN-GB style='mso-ansi-language:EN-GB'>:
Stanford. Founder of Amylin (sold to Bristol-Myers for $5 Billion).<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Financials<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The company
has a very low cash burn due to the initial clinical anti-TNF clinical trials
funded by investments and grants (UK). They have cash on hands for at least 3
years. Financially a very strong company, especially when it’s compared to
other <span class=SpellE>pennystocks</span>. This doesn’t deserve to be a <span
class=SpellE>pennystock</span> and won’t be for long (totally undervalued). The
three companies combined to ATNF were valued at 175M. ATNF currently has a
market cap of 60M<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Additional
information (very low shares float)<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The total outstanding
shares according to <span class=SpellE>Finviz</span> is 5.18M with a 0.97M
float. With increased volume this will for sure take off big time. 50% of the
shares are owned according to the company presentation in November. 60% of
shares are locked up for 12 months.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>What
happened in November?<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>One of the
first thing that will come to mind when you look at the 3M/ 1Y graph is “What
happened in November? Why did it drop form $11 to almost $2”. <o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>First, you
have to understand how SPACs work to get this price movement.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>1) This was
a very old SPAC that started in 2017 and took forever and ever to complete
merger<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>2) Because
of the delays, lot of shareholders “redeemed” their shares (You can do this in
SPACs)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>3) This
gave a false impression that the company might not be good<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>4) This
SPAC had 12 million rights that automatically convert into 1.2 million shares
after merger.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>5) Most of
the right holders bought them between 0.10 and 0.30 (which equates to $1 to $3
in price)<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>6) After
merger, most of the rights holder dumped their shares to lock in profit or
break even rather than wait for the common to go up<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>7) Hence
the big drop from $11 to $2<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>8) The
fundamentals of this company and the team are world class. So, it’s just a
matter of time before it’s true value is reflected in the share price<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>It was
essentially a drop relating to its SPAC structure and execution. Nothing to do
with the fundamentals of the company. But that drop is also why investors now
have such a good opportunity to get in at such a low valuation, which I suspect
won't be the case very long, as investors are finally starting to learn about
ATNF's strong team and prospects moving forward.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>ATNF was a
European company prior to merge. Part of reason it took so long to close, and
it was falsely understood to be a cannabis company (because one of the 3
companies that combined to the current company is developing an anti-TNF drug
from a synthetic CBD compound. Because many mistook it for a European pot
company, it lacked interest needed to make up for the stock rights that were
converted to shares at merger. But again, this is why investors have a great
opportunity now.<o:p></o:p></span></p>

<p class=MsoNormal><b><span lang=EN-GB style='mso-ansi-language:EN-GB'>Technical
set-up<o:p></o:p></span></b></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>The set-up
looks similar to <span class=SpellE>DermTech</span>, Inc. $DMTK. <span
class=SpellE>DermTech</span> does have a low shares float as well. The price
increased from $4 to $42. More about the <span class=SpellE>technicals</span>
of this set-up are explained in a video by 9 Year Millionaire: <a
href="https://www.youtube.com/watch?v=DeO-CxAs-fI&amp;feature=youtu.be">https://www.youtube.com/watch?v=DeO-CxAs-fI&amp;feature=youtu.be</a>
<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'>It reminds
me a lot of $JMIA, when it was around $6 several months ago (now around $40). Both
relatively unknown that have no-brainer huge futures, but took a hit early on
after going public due to structural type issues. In $JMIA it was due to
accounting structure the market didn’t like, and in $ATNF case it was due to a
very lengthy SPAC process/ period with multiple extensions and an oversupply of
stock rights that converted at merger day (when the SPAC merger was completed
and changed to the current ticker symbol). Both of those issues are in the rear
view now- and as soon as the market absorbs the excess shares as people
discover the company- this will shoot back to the $10-11 pre-merge price and
run from there.<o:p></o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'><o:p>&nbsp;</o:p></span></p>

<p class=MsoNormal><span lang=EN-GB style='mso-ansi-language:EN-GB'><o:p>&nbsp;</o:p></span></p>

</div>

</body>

</html>
